1Cooper W, Woloski BMR, Fodero EM, et al. Does treatment with intermittent infusions ofintervenous anti - D allow aproportion of adults with recently diagnosed immune thromblocytopenic purpura to avoid splenectomy.Blood, 2002, (6): 1920 被引量：1
2Bussel JB, Mukherjee R, Stye AJ, et al. Apilot study of rhu - IL - 11treatment of refractory IFP. AmJ Hematol, 2001,66:172 被引量：1
3Perotta A, Sunneberg JA, Scott V, et al. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpur(ITP). Blood, 1999,94:14a 被引量：1
4Cahill MR, Macey MG, Cavenagh JD, et al. Protein A immunoolsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit. Br J Haematol, 1998,100:358 被引量：1
8Shanafeh T D,Madueme H L,Wolf R C,et al. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura,autoimmunc hemolytic anemia,and Evans syndrome [ J]. Mayo Clin Proc ,2003,78 ( 11 ) : 1340-1346. 被引量：1
9Looney RJ, Anolik J, Sanz L B cell as therapeutic targets rheumalic diseases. Current opinion in rheumatology, 2004,16 (3) : 180 - 185. 被引量：1
10Ames PR,Tommasino C, Fossati G, et al. Liraileal effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol,2007,86 ( 3 ) :227 - 228. 被引量：1
